Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial
Quantum BioPharma (NASDAQ: QNTM) has announced successful results from a double-blind, randomized, placebo-controlled clinical trial for unbuzzd™, their dietary supplement designed to combat alcohol intoxication effects. The study demonstrated that unbuzzd™ accelerated blood alcohol concentration (BAC) reduction by over 40% within 30 minutes compared to placebo.
Key findings showed statistically significant improvements in:
- Alcohol metabolism acceleration
- Enhanced alertness within 30 minutes
- Stabilized heart rate and blood pressure
- Reduced perceived impairment and mental fatigue
- 67% reduction in hangover headache severity
The trial included participants aged 21-43 of both genders, with weights ranging from 119-232 pounds. The product showed no adverse effects and was well-tolerated by all participants. unbuzzd™ is currently licensed to Celly Nutrition Corp. and available for purchase.
Quantum BioPharma (NASDAQ: QNTM) ha annunciato risultati positivi da uno studio clinico doppio cieco, randomizzato e controllato con placebo per unbuzzd™, il loro integratore alimentare progettato per contrastare gli effetti dell'intossicazione da alcol. Lo studio ha dimostrato che unbuzzd™ ha accelerato la riduzione della concentrazione di alcol nel sangue (BAC) di oltre il 40% in 30 minuti rispetto al placebo.
I principali risultati hanno mostrato miglioramenti statisticamente significativi in:
- Acceleratione del metabolismo dell'alcol
- Aumento della vigilanza entro 30 minuti
- Stabilizzazione della frequenza cardiaca e della pressione sanguigna
- Riduzione della percezione di compromissione e della fatica mentale
- Riduzione del 67% della gravità del mal di testa da postumi di unalcolica
Lo studio ha incluso partecipanti di età compresa tra 21 e 43 anni di entrambi i sessi, con pesi variabili da 119 a 232 libbre. Il prodotto non ha mostrato effetti avversi ed è stato ben tollerato da tutti i partecipanti. unbuzzd™ è attualmente licenziato a Celly Nutrition Corp. ed è disponibile per l'acquisto.
Quantum BioPharma (NASDAQ: QNTM) ha anunciado resultados exitosos de un ensayo clínico doble ciego, aleatorizado y controlado con placebo para unbuzzd™, su suplemento dietético diseñado para combatir los efectos de la intoxicación por alcohol. El estudio demostró que unbuzzd™ aceleró la reducción de la concentración de alcohol en sangre (BAC) en más del 40% en 30 minutos en comparación con el placebo.
Los hallazgos clave mostraron mejoras estadísticamente significativas en:
- Aceleración del metabolismo del alcohol
- Aumento de la alerta en 30 minutos
- Estabilización de la frecuencia cardíaca y la presión arterial
- Reducción de la percepción de disminución y fatiga mental
- Reducción del 67% en la gravedad del dolor de cabeza por resaca
El ensayo incluyó participantes de 21 a 43 años de ambos sexos, con pesos que variaban de 119 a 232 libras. El producto no mostró efectos adversos y fue bien tolerado por todos los participantes. unbuzzd™ está actualmente licenciado a Celly Nutrition Corp. y está disponible para su compra.
Quantum BioPharma (NASDAQ: QNTM)는 알코올 중독 효과를 완화하기 위한 그들의 건강 보조제 unbuzzd™에 대한 이중 블라인드, 무작위 배정, 위약 대조 임상 시험에서 성공적인 결과를 발표했습니다. 연구 결과 unbuzzd™는 30분 이내에 혈중 알코올 농도(BAC)를 40% 이상 감소시키는 데 기여했습니다는 것이 확인되었습니다.
주요 발견 사항은 다음과 같은 통계적으로 유의미한 개선을 보여주었습니다:
- 알코올 대사 가속화
- 30분 이내의 경각심 향상
- 심박수 및 혈압 안정화
- 감지된 지각 저하 및 정신적 피로 감소
- 숙취 두통의 강도 67% 감소
이 시험에는 21세에서 43세 사이의 남녀 참가자가 포함되었으며, 체중은 119파운드에서 232파운드 사이였습니다. 이 제품은 부작용 없이 모든 참가자에게 잘 견딜 수 있었습니다. unbuzzd™는 현재 Celly Nutrition Corp.에 라이센스가 부여되어 있으며 구매 가능합니다.
Quantum BioPharma (NASDAQ: QNTM) a annoncé des résultats positifs d'un essai clinique en double aveugle, randomisé et contrôlé par placebo pour unbuzzd™, leur complément alimentaire conçu pour lutter contre les effets de l'intoxication alcoolique. L'étude a montré que unbuzzd™ accélérait la réduction de la concentration d'alcool dans le sang (BAC) de plus de 40% en 30 minutes par rapport au placebo.
Les résultats clés ont montré des améliorations statistiquement significatives dans:
- Accélération du métabolisme de l'alcool
- Augmentation de la vigilance dans les 30 minutes
- Stabilisation du rythme cardiaque et de la pression artérielle
- Réduction de la perception de l'handicap et de la fatigue mentale
- Réduction de 67% de la gravité des maux de tête liés à la gueule de bois
L'essai a inclus des participants âgés de 21 à 43 ans de tous deux sexes, pesant entre 119 et 232 livres. Le produit n'a montré aucun effet indésirable et a été bien toléré par tous les participants. unbuzzd™ est actuellement sous licence auprès de Celly Nutrition Corp. et disponible à l'achat.
Quantum BioPharma (NASDAQ: QNTM) hat erfolgreiche Ergebnisse einer doppelt-blinden, randomisierten, placebo-kontrollierten klinischen Studie für unbuzzd™, ihr Nahrungsergänzungsmittel zur Bekämpfung der Alkoholintoxikationswirkungen, bekannt gegeben. Die Studie zeigte, dass unbuzzd™ die Blutalkoholkonzentration (BAC) innerhalb von 30 Minuten um über 40% beschleunigte im Vergleich zu Placebo.
Wesentliche Ergebnisse zeigten statistisch signifikante Verbesserungen in:
- Beschleunigung des Alkoholstoffwechsels
- Erhöhte Wachsamkeit innerhalb von 30 Minuten
- Stabilisierung der Herzfrequenz und des Blutdrucks
- Reduzierte wahrgenommene Beeinträchtigung und mentale Müdigkeit
- 67%ige Reduzierung der Schwere von Katerkopfschmerzen
Die Studie umfasste Teilnehmer im Alter von 21 bis 43 Jahren beider Geschlechter mit einem Gewicht zwischen 119 und 232 Pfund. Das Produkt zeigte keine Nebenwirkungen und wurde von allen Teilnehmern gut vertragen. unbuzzd™ ist derzeit an Celly Nutrition Corp. lizenziert und zum Kauf erhältlich.
- Clinical trial demonstrated 40% faster BAC reduction within 30 minutes
- Statistically significant improvements in alertness and cognitive function
- 67% reduction in hangover headache severity
- No adverse effects reported in clinical trial
- Product already commercialized and available for purchase
- Product is classified as dietary supplement, not a pharmaceutical drug
- Results may vary among individuals as stated in disclaimer
- Cannot be used to justify operating vehicles after alcohol consumption
Insights
The successful completion of unbuzzd™'s clinical trial represents a significant milestone for Quantum BioPharma, with several compelling implications for investors:
Trial Design & Results Excellence: The study employed a gold-standard double-blind, randomized, placebo-controlled crossover design, which provides the highest level of evidence in clinical research. The diverse participant demographics (age 21-43, weight 119-232 lbs) enhance result generalizability. The 40% acceleration in BAC reduction and 67% decrease in hangover severity are particularly noteworthy metrics that exceed typical efficacy thresholds for comparable products.
Market Opportunity & Competitive Advantage: The global hangover cure products market, valued at approximately
Commercial & Financial Implications: The successful trial positions Quantum for potential:
- Increased market share in the growing dietary supplement sector
- Premium pricing justification based on clinical validation
- Licensing opportunities and potential partnerships
- Enhanced intellectual property protection
Risk Considerations: While positive, investors should note:
- The need for post-market surveillance to confirm long-term safety
- Potential regulatory scrutiny given the alcohol-related claims
- Competition from both established and emerging players
- The importance of marketing execution to capitalize on clinical advantages
This clinical trial success positions unbuzzd™ at the intersection of several favorable market dynamics:
Market Timing & Consumer Trends: The product aligns perfectly with the growing 'better-for-you' alcohol consumption trend and increasing health consciousness among millennials and Gen Z. The clinical validation arrives as consumers increasingly demand evidence-based wellness solutions.
Distribution & Growth Strategy: The existing licensing agreement with Celly Nutrition Corp. and established e-commerce presence through unbuzzd.com provide immediate commercialization channels. The clinical data strengthens the case for:
- Expansion into premium retail channels
- Partnerships with major beverage companies
- International market entry, particularly given the multi-exchange listing (NASDAQ, CSE, FRA)
Competitive Landscape Impact: The statistically significant results create substantial barriers to entry, as competitors would need to invest significantly in similar clinical trials to make comparable claims. This scientific validation differentiates unbuzzd™ from the numerous unproven hangover remedies in the market.
Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover
TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has completed a double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product unbuzzd™, investigating its effects on alcohol intoxication and alcohol metabolism.
Results of data analysis show definitively that unbuzzd™ accelerated the rate at which Blood Alcohol Concentration (“BAC”) was reduced in study subjects, while simultaneously reducing the symptoms of intoxication and hangover. All these results were statistically significant compared to placebo. Study participants were both male and female and between the ages of 21 and 43, with weights ranging from 119 to 232 pounds.
The positive effects of unbuzzd™ were rapidly apparent, occurring within 30 minutes after consumption of the dissolved powder. unbuzzd™ was well-tolerated and safe, with no reported product-related adverse effects.
Key findings from the clinical trial include:
- Accelerated Alcohol Metabolism: unbuzzd™ dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was, on average for most participants, more than 40 percent faster within 30 minutes of consuming unbuzzd™ compared to control subjects. This faster reduction of BAC after consuming unbuzzd™ was both statistically significant compared to placebo and was observed at each subsequent measurement of BAC over a four-hour period.
- Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd™. Participants felt more alert and made fewer cognitive errors within 30 minutes of consuming unbuzzd™, significantly outperforming placebo results.
- Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd™ lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was statistically significant.
- Reduced Perceived Impairment and Mental Fatigue: unbuzzd™ helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication.
- Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment, and reduced headache compared to placebo results, at both four hours (67 percent reduction in headache severity) and eight hours after consuming unbuzzd™.
- No Side Effects: unbuzzd™ was well-tolerated by all study participants, with no reported adverse side effects.
unbuzzd™ is a proprietary blend of vitamins and supplements developed by a world-class team of scientists at biopharmaceutical company Quantum BioPharma. This double-blind, placebo-controlled crossover study shows, with statistical significance, that unbuzzd™ accelerates the metabolism of alcohol and speeds the lowering of blood alcohol concentration. Concurrently, study participants rapidly restored their mental alertness, reduced their perceived impairment and fatigue, and avoided the worst effects of a hangover.
“We are thrilled to see such significant and meaningful outcomes in this clinical study. This study confirms the exceptional overall performance of unbuzzd™ to help reduce the acute effects of alcohol intoxication,” said Dr. Andrzej Chruscinski, Vice President of Clinical and Scientific Affairs at Quantum Biopharma. “We are also pleased to see that there were no product-related side effects or safety concerns in this clinical study.”
Zeeshan Saeed, CEO of Quantum BioPharma added, “This clinical trial shows that unbuzzd™ is an important addition to the safe and responsible consumption of alcohol. Consumers now have the benefit of knowing that unbuzzd™ can reduce alcohol intoxication, speed the reduction of blood alcohol concentration, restore mental alertness and well-being, and help them avoid the worst symptoms of a hangover.”
The formula for unbuzzd™ is licensed to Celly Nutrition Corp. and is currently available at https://unbuzzd.com. unbuzzd™ is a registered trademark of Celly Nutrition Corp.
Individual results may vary. unbuzzd™ is a dietary supplement. Consuming unbuzzd™ after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such.
Forward-looking information in this press release are based on certain assumptions and expected future events.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
QNTM@mzgroup.us
www.mzgroup.us
FAQ
What were the key results of QNTM's unbuzzd clinical trial in February 2025?
How quickly does unbuzzd (QNTM) start working after alcohol consumption?
What age groups were included in QNTM's unbuzzd clinical trial?
Were there any side effects reported in QNTM's unbuzzd trial?
What is the regulatory classification of QNTM's unbuzzd product?
